Eagle Pharmaceuticals Announces Laboratory Test Results Demonstrating In Vitro Antiviral Activity of RYANODEX® (dantrolene sodium) Against Coronavirus SARS-CoV-2
Eagle Pharmaceuticals, Inc. (EGRX)
Last eagle pharmaceuticals, inc. earnings: 3/2 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.eagleus.com
Company Research
Source: Business Wire
IND Submitted to FDA for Planned Clinical Study at Hackensack University Medical Center to Evaluate RYANODEX for Treatment of COVID-19 Patients WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”), a New Jersey-based pharmaceutical company, today announced that its product RYANODEX® (dantrolene sodium) for injectable suspension inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic, in a controlled in vitro laboratory test. On Tuesday, April 14, Eagle submitted its Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for a Phase 2 clinical trial in partnership with Hackensack University Medical Center to evaluate the efficacy of RYANODEX in patients infected with SARS-CoV-2. Eagle has been in contact with the FDA’s Coronavirus Treatment Acceleration Program (“CTAP”) to request potential expedited review of the IND application and aims to begin the clinical trial as soon as possible.
Show less
Read more
Impact Snapshot
Event Time:
EGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EGRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EGRX alerts
High impacting Eagle Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EGRX
News
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration [Yahoo! Finance]Yahoo! Finance
- Eagle Announces Update on Delisting from Nasdaq and SEC DeregistrationGlobeNewswire
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial OfficerGlobeNewswire
EGRX
Sec Filings
- 11/19/24 - Form 3
- 11/15/24 - Form 8-K
- 11/14/24 - Form SC
- EGRX's page on the SEC website